Loading...
Loading...
Atrium Therapeutics Inc · Biotechnology
Small/Mid Cap
Atrium Therapeutics Inc's TraderMatrix Quality Score is 45/100 (Weak), a 0–100 read on profitability, valuation, balance-sheet safety, growth and (for dividend payers) payout safety. Atrium Therapeutics Inc is a Biotechnology company in the small/mid cap tier.
RNA ranks #10 of 32 in the Biotechnology sector by Quality Score. Closest scores:
Quality Score is a 0–100 composite rating blending profitability, valuation, balance-sheet safety, growth and (for dividend payers) payout safety. Higher scores indicate stronger fundamental characteristics. Use it to screen out weak names before selling premium or buying LEAPS. Read the full methodology.
Atrium Therapeutics Inc has a TraderMatrix Quality Score of 45/100, which falls in the "Weak" band. It ranks #10 of 32 in the Biotechnology sector. Scores of 80+ are rated High quality, 65–79 Solid, 50–64 Mixed and below 50 Weak. This is a fundamentals read, not investment advice.
The Quality Score is a 0–100 composite that blends profitability, valuation, balance-sheet safety, growth and (for dividend payers) payout safety into one number. RNA's current score is 45/100.
The score is recalculated as new data arrives. RNA's score of 45/100 was last updated on Aug 28, 2026.
Updated Aug 28, 2026